Long term effects of the implantation of autologous bone marrow mononuclear cells for type 2 diabetes mellitus
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Previous studies have shown that several types of stem cells can differentiate into insulin-secreting islet beta-cells and that these cells can reduce blood glucose in some trials, but there has been no report of a long-term follow-up. We assessed the long-term effects of the use of autologous bone marrow mononuclear cells in the treatment of type 2 diabetes mellitus (T2DM). Based on the willingness to receive implantation of bone marrow mononuclear cells, One hundred and eighteen patients with T2DM were divided into two groups; the patients in group I were treated with autologous bone marrow mononuclear cells and patients in group II were treated with insulin intensification therapy. Mononuclear cells from bone marrow were injected back into the patient's pancreas via a catheter. Patients were followed-up after the operation at monthly intervals for the first 3 months and thereafter every 3 months for the next 33 months, the occurrence of any side effects and the results of laboratory examinations were evaluated. There were no reported acute or chronic side effects in group I and both the HbA1c and C-peptide in group I patients were significantly better than either pretherapy values or group II patients during the follow-up period. These data suggested that the implantation of autologous bone marrow mononuclear cells for the treatment of T2DM is safe and effective. This therapy can partially restore the function of islet beta-cells and maintain blood glucose homeostasis in a longer time.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nishimura, S., Manabe, I., Nagasaki, M., Eto, K., Yamashita, H., Ohsugi, M., Otsu, M., Hara, K., Ueki, K., Sugiura, S., et al. (2009) · Nature Medicine · doi:10.1038/nm.1964 · Cited by 2,230 · cited 1×
“T2DM, characterized by impaired beta-cell functions and reduced insulin sensitivity, accounts for about 90% of all diabetic patients [5-8].”
BackgroundIn vivo reprogramming of adult pancreatic exocrine cells to β-cells
Zhou, Q., Brown, J., Kanarek, A., Rajagopal, J., & Melton, D. A. (2008) · Nature · doi:10.1038/nature07314 · Cited by 2,010
Couri, C. E. B. (2009) · JAMA · doi:10.1001/jama.2009.470 · Cited by 449
Cited by
Bhansali, S., Dutta, P., Kumar, V., Yadav, M. K., Jain, A., Mudaliar, S., Bhansali, S., Sharma, R. R., Jha, V., Marwaha, N., et al. (2017) · Stem Cells and Development · doi:10.1089/scd.2016.0275 · Cited by 126
Yazhen, Z., Wenyi, C., Bing, F., & Hongcui, C. (2020) · Aging and disease · doi:10.14336/ad.2019.0421 · Cited by 82
“Information regarding FPG was available in eight trials that included 177 patients receiving stem cell therapy [17, 23, 30-35].”
MethodRahim, F., Arjmand, B., Shirbandi, K., Payab, M., & Larijani, B. (2018) · Non-coding RNA Investigation · doi:10.21037/sci.2018.11.01 · Cited by 30
Metadata
- Authors
- Hu, J., Li, C., Wang, L., Zhang, X., Zhang, M., Gao, H., Yu, X., Wang, F., Zhao, W., Yan, S., & Wang, Y.
- Venue
- Endocrine Journal
- Publisher
- Japan Endocrine Society
- Published
- 2012
- Volume
- 59
- Issue
- 11
- Pages
- 1031-1039
- ISSN
- 0918-8959 (ISSN-L)
- 1348-4540
- OpenAlex
- W2009600260
- Cited by
- 48
- References
- 3
- FWCI
- 2.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long term effects of the implantation of autologous bone marrow mononuclear cells for type 2 diabetes mellitus. https://app.cochat.ai/papers/10.1507/endocrj.ej12-0092
- The paper
- Hu, J., Li, C., Wang, L., Zhang, X., Zhang, M., Gao, H., Yu, X., Wang, F., Zhao, W., Yan, S., & Wang, Y. (2012). Long term effects of the implantation of autologous bone marrow mononuclear cells for type 2 diabetes mellitus. Endocrine Journal. https://doi.org/10.1507/endocrj.ej12-0092
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.